Check-Cap (NASDAQ:CHEK) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK) in a report released on Saturday. The brokerage issued a sell rating on the medical research company’s stock.

Check-Cap Price Performance

Shares of NASDAQ:CHEK opened at $0.81 on Friday. The company’s 50-day moving average price is $1.11 and its two-hundred day moving average price is $1.23. Check-Cap has a one year low of $0.56 and a one year high of $3.45. The stock has a market capitalization of $4.75 million, a PE ratio of -0.27 and a beta of 0.16.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.